Acro Biomedical Co., Ltd.
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Acro Biomedical Co., Ltd. generated cash of -$147,481, which is less than the previous year. Cash used in financing activities reached the amount of $58,085 last year. Net change in cash is therefore -$89,396.
Cash Flow
| 2014 | 0 | 0 | 10K |
|---|---|---|---|
| 2015 | -48.85K | 0 | 72.2K |
| 2016 | -34.74K | 0 | 10K |
| 2017 | -463.34K | 0 | 497.62K |
| 2018 | -140.41K | 0 | 104.75K |
| 2019 | -59.70K | 0 | 23.01K |
| 2020 | -199.46K | 0 | 216.67K |
| 2021 | 299.33K | 0 | -222.21K |
| 2022 | -147.48K | 0 | 58.08K |
ACBM Cash Flow Statement (2014 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 95.24K | 18.12K | 911 | 37.60K | 36.81K | 2.53K | 27.27K | 3.92K | 0 |
Operating activities | |||||||||
Net income | -15.87M | -7.69M | -117.45K | -371.60K | 419.66K | -2.24K | -43.42K | -47.49K | 0 |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||||
Depreciation and amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Stock-based compensation expense | 15.71M | 7.65M | 0 | 148.39K | 0 | 0 | 0 | 0 | 0 |
| Deferred income tax benefit | 15.71M | 7.65M | 0 | 148.39K | 0 | 0 | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | -40.5K | -598K | -13K | -18.39K | 92.72K | 481K | 0 | 0 | 0 |
Inventories | 0 | 938K | -59.44K | 181.44K | -665.6K | -481K | 0 | 0 | 0 |
Accounts payable | 50.37K | 1.46K | 900 | 16.25K | 6.71K | 50.40K | 6.50K | 825 | 0 |
Cash generated by operating activities | -147.48K | 299.33K | -199.46K | -59.70K | -140.41K | -463.34K | -34.74K | -48.85K | 0 |
Investing activities | |||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Financing activities | |||||||||
Common Stock Issued | 0 | 0 | 0 | 0 | 0 | 500K | 0 | 72.2K | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10K |
Repayments of term debt | 0 | -222.21K | -216.67K | 0 | -500 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 58.08K | -222.21K | 216.67K | 23.01K | 104.75K | 497.62K | 10K | 72.2K | 10K |
Net Change In Cash | -89.39K | 77.12K | 17.21K | -36.69K | -35.66K | 34.27K | -24.74K | 23.35K | 10K |
Cash at end of period | 5.85K | 95.24K | 18.12K | 911 | 1.14K | 36.81K | 2.53K | 27.27K | 10K |
| Data source | Data source | Data source | Data source | Data source | Data source |